Jamieson Wellness (JWEL.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Jamieson Wellness (JWEL.TO)

41.50

-0.05 (0.12%)

as of Aug 5, 2026, 8:00:01 pm Market Open.

153 watching

Investor Insights

Aug 5, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Jamieson Wellness (JWEL-T) is currently viewed positively by market experts, with several indicators pointing towards a strong future. The company has successfully navigated recent market conditions and remains resilient, particularly with its core business performing well. Experts highlight the potential for unsolicited takeout offers, increased demand in international markets like China, and consistent dividend growth of 14% over the past five years. Additionally, Jamieson's strategic acquisitions, including a California-based company, have insulated it from tariff impacts, further bolstering its market position. Analysts set a bullish price target of $42.43, suggesting there could be further upside from current valuations.

Consensus

Buy

Valuation

Undervalued

Similar

Bayer, BAYRY

BUY ON WEAKNESS

A nice company that seems to dominate the vitamin business, which offers long-term growth. Buy this at a decent PE. People buy this when markets are uncertain. Buy below $35.

TOP PICK

Recent price drop has presented good buying opportunity 25% share of the Canadian vitamin and supplement market. Growing international sales with the help of other companies such as Costco. Large acquisition announced last week will provide entry point into the US market. EPS significantly rising (20x ) at the moment.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS at 34 cents that beat estimates by 2%. Sales of $112.3M were reported. Generally a good quarter. The focus on post covid health trends continue to be a tailwind. Attractive here. Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Interesting, good company, profitable. A bit rich now. He was worried about private labels taking market share. Could buy it on the right dip. He's looking at it.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenues beat street estimates by 4%. EBITDA was 2% better at $29M. It is trading at 26x earnings, which is reasonably considering the high growth expectations. There are competitors but they have strong market share. A higher risk buy for growth and some income. Unlock Premium - Try 5i Free

BUY

She does not follow that small a capitalization stock closely. They are a well positioned player in the space. Their growth opportunities look positive.

WATCH

A great company and it has profited from the pandemic. People are becoming more health conscious. It is well-positioned to take advantage of the trend. Earnings still have a ways to grow to make the multiples attractive. Trailing 12-month earnings are .64 cents, which makes it at 36x earnings. He would like to see it more around 25x earnings, around the mid-to-high 20s.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Sales beat expectations by 6% and earnings also beat estimates by 2%. Guidance was raised, which is also positive. The pull back that brought it down 16% is more market related than to do with the stock itself. It is a good time to add to this position. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Covid has helped the company with consumers more aware of health. They beat sale estimates last quarter but missed on EPS. It’s trading within its expected growth rate. The health trend should be sustained even after covid. Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Just looking at your local drug store, all the shelves have been stripped bare for their products. People are taking more supplements and he thinks that will continue. The stock is at 29 times PE, but technically it is bullish. He thinks analysts will continue to increase earnings outlooks to justify the costs.

BUY

A fine IPO performer; they did a good job to ensure that private equity fund involved got cleaned out, so that overhang didn't happen. They just put out a strong report with good international growth. This may be added to an index. Not a cheap stock, but they boast earnings growth and a strong brand. He owns a lot of this.

HOLD

They did a good job of getting the private equity guys out of it so there was lots for individual investors. They are gearing up for a better second half.

HOLD

Vitamins and health supplements, protein supplements. They missed on earnings. It is a great Canadian company. A pickup in the cold and flu season would benefit them. They are trying to penetrate the Chinese market. They Manufacture in Winsor and Scarborough.

WATCH

A stable, high-quality business. When it IPO'd, the market over-rewarded it, but the stock has since corrected to something attractive. The healthy trend works for them. he's studying it.

Showing 16 to 30 of 35 entries

Most Recent Experts

Jerome Hass

Lightwater Partners

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

The Monthly Gems by Allan Tong

Stockchase

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Jamieson Wellness (JWEL.TO)